Ribavirin plasma concentration predicts sustained virological response to peginterferon alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 428-430

  Breilh, Dominique ^a   Djabarouti, Sarah ^a   Trimoulet, Pascale ^a   Bail, Brigitte Le ^b   Dupon, Michel ^b   Ragnaud, Jean Marie ^b   Fleury, Hervé ^a   Saux, Marie Claude ^a   Thiébaut, Rodolphe ^c   Chêne, Geneviève ^d   Neau, Didier ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

^c INSERM   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 70350536647     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b62858     Document Type: Letter

References (10)

1. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21: 1073-1089.
2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351:438-450.
3. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008;47: 1453-1461.
4. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother. 2008;61:919-924.
5. Svensson JO, Bruchfeld A, Schvarcz R, et al. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chro-matography. Ther Drug Monit. 2000;22: 215-218.
6. Loregian A, Scarpa MC, Pagni S, et al. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856:358-364.
7. Myers RP, Benhamou Y, Bochet M, et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-res-ponders and relapsers to IFN-based therapy. AIDS. 2004;18:75-79.
8. Crespo M, Mira JA, Pineda J, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother. 2008;62:793-796.
9. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus coinfected patients. J Acquir Immune Defic Syndr. 2005; 39:401-405.
10. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegy-lated interferon and viral responses in patients infected with HIVand HCV. J Med Virol. 2008; 80:1523-1529.